🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 18 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
10/02/2021 64,58 65,49 63,35 63,74 -0,02% 3,31% 365.500
09/02/2021 64,16 64,43 63,10 63,75 -0,30% 2,07% 286.500
08/02/2021 63,59 66,01 61,15 63,94 +0,61% 7,64% 396.700
05/02/2021 60,00 64,68 59,45 63,55 +0,75% 8,71% 954.700
04/02/2021 60,93 63,85 60,01 63,08 +3,80% 6,30% 583.500
03/02/2021 59,96 61,89 59,96 60,77 +0,88% 3,22% 421.000
02/02/2021 57,64 61,62 57,25 60,24 +6,08% 7,58% 769.900
01/02/2021 58,98 59,36 55,91 56,79 -1,78% 5,85% 674.200
29/01/2021 56,09 59,08 55,47 57,82 +2,57% 6,44% 928.800
28/01/2021 56,73 58,45 56,00 56,37 -0,53% 4,32% 502.300
27/01/2021 60,03 60,44 55,68 56,67 -7,37% 7,93% 912.600
26/01/2021 63,52 63,52 60,82 61,18 -3,68% 4,25% 248.500
25/01/2021 63,25 63,61 60,69 63,52 +0,25% 4,62% 340.900
22/01/2021 62,34 64,13 62,25 63,36 +0,49% 3,02% 405.000
21/01/2021 63,48 65,06 62,26 63,05 -1,17% 4,41% 248.800
20/01/2021 65,64 66,64 63,38 63,80 -2,78% 4,97% 686.200
19/01/2021 68,55 68,85 65,30 65,62 -4,19% 5,18% 673.000
15/01/2021 68,32 69,48 67,59 68,49 -0,33% 2,77% 247.300
14/01/2021 67,13 68,88 66,58 68,72 +3,12% 3,43% 309.600
13/01/2021 66,57 67,59 65,89 66,64 -0,61% 2,55% 280.500
12/01/2021 66,33 68,52 66,33 67,05 +1,18% 3,29% 314.000
11/01/2021 66,36 67,81 66,19 66,27 -1,94% 2,44% 336.900
08/01/2021 68,25 70,82 65,58 67,58 -1,94% 7,68% 611.100
07/01/2021 66,51 68,98 66,51 68,92 +3,65% 3,71% 497.000
06/01/2021 64,92 67,28 64,24 66,49 +2,62% 4,69% 482.000
05/01/2021 61,52 65,04 61,14 64,79 +7,09% 6,34% 648.400
04/01/2021 60,65 61,36 59,71 60,50 -0,87% 2,72% 1.046.600
31/12/2020 61,39 61,87 60,07 61,03 -0,08% 2,93% 230.400
30/12/2020 63,73 63,73 60,89 61,08 -3,74% 4,46% 612.000
29/12/2020 63,95 64,53 62,25 63,45 -1,06% 3,57% 217.700